Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Work In Process (2020 - 2025)

Historic Work In Process for Puma Biotechnology (PBYI) over the last 6 years, with Q3 2025 value amounting to $5.4 million.

  • Puma Biotechnology's Work In Process rose 16907.73% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year increase of 16907.73%. This contributed to the annual value of $758000.0 for FY2024, which is 756.1% down from last year.
  • As of Q3 2025, Puma Biotechnology's Work In Process stood at $5.4 million, which was up 16907.73% from $1.3 million recorded in Q2 2025.
  • Over the past 5 years, Puma Biotechnology's Work In Process peaked at $7.8 million during Q2 2024, and registered a low of $758000.0 during Q4 2024.
  • Moreover, its 5-year median value for Work In Process was $2.1 million (2024), whereas its average is $2.6 million.
  • Examining YoY changes over the last 5 years, Puma Biotechnology's Work In Process showed a top increase of 16907.73% in 2025 and a maximum decrease of 8288.91% in 2025.
  • Quarter analysis of 5 years shows Puma Biotechnology's Work In Process stood at $1.4 million in 2021, then surged by 92.13% to $2.7 million in 2022, then crashed by 69.18% to $820000.0 in 2023, then fell by 7.56% to $758000.0 in 2024, then skyrocketed by 611.74% to $5.4 million in 2025.
  • Its last three reported values are $5.4 million in Q3 2025, $1.3 million for Q2 2025, and $1.1 million during Q1 2025.